Improving efficacy, efficiency and economics of hospice individualized drug therapy

American Journal of Hospice and Palliative Medicine

Volumn 19, Issue 2, 2002, Pages 135-138

  Lycan, Jeff ^a   Grauer, Phyllis ^b   Mihalyo, Mary ^c,d   Houchen, Betsy ^e  

^a Ohio Hospice Palliative Care Organization   (United States)

^b OHIO NORTHERN UNIVERSITY   (United States)

^c DUQUESNE UNIVERSITY   (United States)

^d Palliative Care Consulting Group   (United States)

^e LLP   (United States)

Author keywords

clinical pharmacist; hospice pharmacy costs; pharmacy and therapeutics committee; preferred drug list

Indexed keywords

COST BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPICE CARE; HUMAN; REVIEW; STANDARD; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DRUG THERAPY; HEALTH CARE COSTS; HOSPICE CARE; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY OF HEALTH CARE;

EID: 0036512624     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910201900213     Document Type: Article

References (5)

1. Medical Group Practice Digest. Managed Care Digest Series 2000. Aventis Pharmaceuticals Inc., 2000, 30–31.
2. Findlay SD: Direct-to-consumer promotion of prescription drugs: Economic implications for patients, payers and providers. Pharmacoeconomics. 2001; 19(2): 109–119.
3. Barrett A, Carey J: Drug Prices: Whatʼns fair? How can we encourage research and still keep prices within reach…for cipro and beyond? Businessweek. Dec. 10, 2001.
4. McPherson, ML: Performing a medication regimen review in hospice and palliative care. Am J Hospice and Palliative Care. 2001; 18(3): 193–199.
5. ACCP Position Statement. Practice guidelines for pharmacotherapy specialists. Pharmacotherapy. 2000; 20(4): 487–490.